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ABSTRACT 
Impact of Adverse Childhood Experiences on Mental Health Outcomes and Related Prescription 
Practices in a Psychiatric Inpatient Sample 
by 
Carrie LeMay 
A definitive association between adverse childhood experiences (ACEs) and negative physical 
and mental health outcomes has been established. There is evidence that individuals in forensic 
psychiatric facilities are disproportionately exposed to ACEs, which may impact severity, 
prognosis, and age of onset of psychiatric symptoms, including behavioral concerns of 
institutional aggression, self-harm behaviors, and suicide attempts. Such psychiatric and 
behavioral concerns are often managed through multiple psychotropic prescriptions, leading to 
psychotropic polypharmacy. This study evaluated the relationship between ACEs, mental health 
and behavioral concerns, and psychotropic polypharmacy through analysis of archival data from 
a forensic inpatient psychiatric facility. A total of 182 patients met inclusion criteria. Through a 
comprehensive record review, ACE scores, mental health outcomes, behavioral concerns, and 
prescription practices were ascertained and subjected to a series of regression analyses. Results 
indicate that the current participants experience greater prevalence of ACEs and mental health 
outcomes, as well as higher rates of psychotropic polypharmacy. These relationships are 
mediated by history of self-harm behaviors. The higher polypharmacy rates yield greater 
negative side effects with the need to manage with additional medications. Taken as a whole, 
ACEs are a relevant consideration, as childhood adversity may lead to a lifetime of difficulty 
with managing emotional distress and symptoms of psychopathology. Pharmacological treatment 
may be necessary, particularly with those who experience more complex mental health 
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outcomes. However, a primary focus on psychotropic intervention can result in high rates of 
medications and polypharmacy with significant side effects. Incorporation of non-
pharmacological intervention should be a primary consideration with forensic inpatients to 
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Adverse Childhood Experiences 
 Adverse Childhood Experiences (ACEs) describe occurrences of abuse, neglect, and 
household dysfunction during childhood and adolescence. Childhood abuse and neglect are a 
significant burden to children and adolescents around the world, with ranging rates of reported 
emotional abuse (11-47%), physical abuse (14-55%), sexual abuse (6-22%), emotional neglect 
(15-40%), and physical neglect (7-19%) (Stoltenborgh, Bakermans-Kranenburg, Alink, & van 
Ijzendoom, 2015). However, ACEs are not confined to only these forms of maltreatment. 
Ongoing ACE study research has defined ten different types of childhood adversities, 
additionally including parental separation or divorce, domestic violence in the household, and 
household member substance abuse, mental illness, and incarceration (Centers for Disease 
Control; CDC, 2013; Felitti et al., 1998). 
Historically, research has emphasized the impact of singular events of trauma or 
maltreatment on long-term outcomes.  Little was known of the impact of cumulative adversity on 
adult physical and mental health outcomes until the initial ACE survey research. The original 
study focusing on ACEs (Felitti et al., 1998), as well as a second wave of data collection (CDC, 
2013), was conducted from 1995 to 1997 by Kaiser Permanente at their Health Appraisal Clinic 
in San Diego by examining patients and their medical records. Their purpose was to examine 
factors related to health outcomes, health care utilization, and causes of death. After medical 
evaluation, 17,337 patients completed a questionnaire that specifically assessed a range of 
factors, of which the most important were 10 specific indicators of childhood maltreatment and 
family dysfunction (i.e., verbal/emotional, physical, and sexual abuse; emotional and physical 
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neglect; domestic violence in the household; parental separation or divorce; and household 
member substance abuse, mental illness, and incarceration (CDC, 2013; Felitti et al., 1998). 
Results from over nine thousand patients revealed that just over half of participants reported 
experiences of one or more adversities, while 6.2% reported four or more (Felitti et al., 1998). 
Results from two combined waves of collection showed that over two thirds of respondents 
endorsed at least one ACE, and one in five reported three or more (CDC, 2013). Felitti et al. 
(1998) found significant associations between ACEs and numerous medical conditions, 
including self-reported fair or poor health, chronic obstructive pulmonary disease, diabetes, heart 
disease, cancer, stroke, hepatitis, and skeletal fractures. ACEs were additionally linked to various 
health risk factors, such as depression, suicide attempts, sedentary lifestyle, obesity, smoking, 
alcoholism, intravenous and illicit drug use, and having fifty or more sexual partners (Felitti et 
al., 1998). 
 Examining outcomes using ACE survey methodology has advanced our understanding of 
the impact of cumulative childhood adversity across the lifespan. The more ACEs an individual 
experiences, the greater their decline in functioning across various domains (Mersky, Topitze, & 
Reynolds, 2013). These high risk behaviors further contribute to negative physical and mental 
health outcomes (CDC, 2013). Collectively, ACE research indicates that the impact of ACEs on 
long-term adult physical and mental health is additive and exponential, meaning, as the number 
of ACEs to which an individual is exposed increases, the risk for and occurrence of health 
related problems also increases.  
Common interventions for both physical and mental health problems include 
pharmacology, especially as health issues compound. As a medication regimen becomes more 
complex, as might be showcased by an individual diagnosed with both physical and mental 
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health problems or co-morbid mental illnesses, the risk for negative consequences, including 
drug interactions, side effects, and even death, increases. Yet these potential consequences are 
often misunderstood, overlooked, or ignored in the pursuit of treating specific conditions and 
related symptoms (Rambhade, Chakarborty, Shrivastava, Patil, & Rambhade, 2012).  
Only limited research describing associations between ACEs, health outcomes, and 
polypharmacy is available. Further, no published studies to date have examined these 
relationships in forensic and inpatient mental health populations, despite the evidence that these 
populations are disproportionately exposed to maltreatment and household dysfunction in 
childhood, frequently have higher rates of physical and mental health problems, and are usually 
treated with multiple forms of medications in response to health and behavioral needs. To 
address gaps in existing research, the relationship between adverse childhood experiences, health 
outcomes, and prescription practices will be examined within a forensic inpatient setting. 
Below, I will discuss the impact of adverse childhood experiences on health outcomes in 
community, offender, and psychiatric settings. Additionally, definitions of polypharmacy, 
associated polypharmacy practices, and the potential benefits and risks of these medication 
regimens will be reviewed.  
Childhood Adversity and Health Outcomes 
 Previous literature has definitively linked experiences of childhood trauma and household 
dysfunction with health risk behaviors and negative physical and mental health outcomes. These 
associations are briefly described below. 
Health Risk Behaviors  
Persons exposed to maltreatment and adversity in childhood are at increased risk of 
engaging in behaviors in adolescence and adulthood that put their health at risk (Draper et al., 
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2008). These health-risk behaviors impact the development and course of physical and mental 
illness (Felitti, 2009; Mersky et al., 2013). Research links ACEs to such health-risk behaviors as 
drinking alcohol (Bellis, Lowey, Leckenby, Hughes, & Harrison, 2014; Mersky et al., 2013), 
smoking tobacco (Anda et al., 1999; Campbell, Walker, &Egede, 2016; Ford et al., 2011; Walsh 
& Cawthon, 2014), using intravenous and illicit drugs (Allem, Soto, Baezconde-Garbanati, & 
Unger, 2015; Dube, Felitti, Dong, Chapman, Giles, & Anda, 2003; Mersky et al., 2013; Wu, 
Schairer, Dellor, & Grella, 2010), physical inactivity (Bellis et al., 2014) and high-risk sexual 
activity (Bellis et al., 2014). Engaging in these types of risky behaviors is more likely to occur 
earlier and more frequently with increasing exposure to childhood trauma and household 
dysfunction (Bellis et al., 2014; Marie-Mitchell & O’Connor, 2013). Increased exposure to ACEs 
and related health-risk behaviors has also been shown to lead to such things as teenage 
pregnancy (CDC, 2013), preterm birth (Christiaens, Hegadoren, & Olsen, 2015) and sexually 
transmitted diseases (Wilson & Widom, 2008), as well as developing alcohol (Dube et al., 2006; 
Pilowsky, Keyes, & Hasin, 2009) and substance dependence (Bellis et al., 2014; Douglas et al., 
2010).   
Physical Health Outcomes 
Exposure to childhood adversity has been linked to poor self-rated health (Felitti et al., 
1998; Mersky et al., 2013) and a variety of physical health outcomes, many of which are 
mediated by the presence of health-risk behaviors. These forms of morbidity include various 
forms of cardiovascular disease, liver disease, obesity, diabetes, emphysema, chronic obstructive 
pulmonary disease, asthma, stroke, cancer, hepatitis, autoimmune disease, fibromyalgia, skeletal 
fractures, chronic headaches, chronic pain, and irritable bowel syndrome (Anda, Brown, Dube, 
Bremner, Felitti, & Giles, 2008; Anda, Tietjen, Schulman, Felitti, & Croft, 2010; Bellis et al., 
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2014; Campbell et al., 2016; Chartier & Walker, 2009; Danese & Tan, 2014; Dube, Fairweather, 
Pearson, Felitti, Anda, & Croft, 2009; Dong, Dube, Felitti, Giles, & Anda, 2003; Dong et al., 
2004; Felitti et al., 1998; Gilbert et al., 2015; Gunstad et al., 2006; Mersky et al., 2013). As a 
result, exposure to cumulative ACEs has also been associated with premature death and mortality 
(Brown et al., 2010; Kelly-Irving et al., 2013). With the exception of smoking tobacco, Brown 
and colleagues (2009) concluded that the relationship between ACEs, engagement in health-risk 
behaviors, and diagnosis of several chronic diseases have a modest relationship, with evidence 
suggesting stronger associations with higher-end ACE scores. 
Mental Health Outcomes 
The strongest associations between ACEs and adult outcomes relate to mental health 
concerns (Brown et al., 2009). Similar to physical health outcomes, ACEs have a cumulative 
negative impact on mental health (Mersky et al., 2013), with higher ACEs associated with 
greater frequency of self-reported mental distress and psychopathology (e.g., Anda et al., 2005; 
Chapman, Dube, & Anda, 2007; Chapman, Whitfield, Felitti, Dube, Edwards, & Anda, 2004; 
Gilbert et al., 2015).  ACEs play a key role in the development of specific psychopathologies, 
such as anxiety (Benjet, Borges, & Medina-Mora, 2010), phobias (Spinhoven et al., 2010), post-
traumatic stress disorder (Brockie, Dana-Sacco, Wallen, Wilcox, & Campbell, 2015), sleep 
disorders (Kajeepeta, Gelaye, Jackson, & Williams, 2015), hallucinations (Whitfield, Dube, 
Felitti, & Anda, 2005), psychosis (Anda, Brown, Felitti, Bremner, Dube, & Giles, 2007; 
Koskenvuo & Koskenvuo, 2015; Varese et al., 2012), personality disorders (Afifi et al., 2011), 
autobiographical memory disturbances (Edwards, Fivush, Anda, Felitti, & Nordenber, 2001), 
problematic substance use (Benjet et al., 2010; Brockie et al., 2015), mood disorders (Benjet et 
al., 2010; Mersky et al., 2013) and depression (Brockie et al., 2015; Chapman et al., 2004; 
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Spinhoven et al., 2010), as well as suicidal ideation (Turner, Finkelhor, Shattuck, & Hamby, 
2012) and suicidal behaviors (Bellis et al., 2014; Brockie et al., 2015; Dudeck et al., 2016).  
ACEs have been additionally associated with externalizing problems, including antisocial 
behavior (Schilling, Aseltine Jr., & Gore, 2007; Reavis, Looman, Franco, & Rojas, 2013), 
interpersonal violence and aggression (Duke, Pettingell, McMorris, & Borowsky, 2010; Odgers 
et al., 2008), juvenile delinquency (Fox, Perez, Cass, Baglivio, & Epps, 2015), impulsivity 
(Duke, Pettingell, McMorris, & Borowsky, 2010), and attention deficit hyperactivity disorder 
(Brown, Brown, Briggs, German, Belamarich, & Oyeku, 2016; Fuller-Thomson & Lewis, 2015).  
ACEs in Forensic Mental Health Patients 
 Research indicates that as a person is exposed to childhood adversity, their likelihood for 
experiencing more than one of the aforementioned physical or mental illnesses also increases, 
even after controlling for health-risk behaviors and other psychosocial factors (Sinnott, McHugh, 
Fitzgerald, Bradley, & Kearney, 2015); however, a great majority of the studies evidencing this 
relationship have examined only community samples. Relatively few studies have been 
conducted in psychiatric or forensic populations, despite evidence that these populations are 
disproportionately exposed to childhood abuse, neglect, and household dysfunction (Baglivio, 
Epps, Swartz, Sayedul Huq, Sheer, & Hardt, 2014; Rytila-Manninen et al., 2014). 
Childhood Adversity and Psychiatric Populations 
Research has investigated the relationship between singular types of abuse in childhood 
and various forms of serious mental illness (e.g., Spidel, Lecomte, Greaves, Sahlstrom, & Yuille, 
2010), but only in the last two decades has the cumulative impact of childhood maltreatment and 
household dysfunction been considered. Total ACE score has been associated with serious 
mental illness diagnosis (Sacco, Head, Vessicchio, Easton, Prigerson, & George, 2007). In a 
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review, Grubaugh and colleagues (2011) reported that 90% of adults with serious mental illness 
have experienced at least one adverse experience in childhood. One study found that 46% of 
individuals with serious mental illness reported experiencing at least three ACEs (Rosenberg, Lu, 
Mueser, Jankowski, & Cournos, 2007), while another study reported that 38.9% of people with 
serious mental illness reported four or more childhood adversities (Stumbo, Yarborough, 
Paulson, & Green, 2015).  
Experiencing adversity earlier in life, particularly during childhood, may lead to earlier 
onset of mental health problems (McLaughlin, Green, Gruber, Sampson, Zaslavsky, & Kessler, 
2010; Schalinski, Teicher, Nischk, Hinderer, Muller, & Rockstroh, 2016) and more severe 
psychiatric symptoms in adulthood (Schalinski et al., 2016; Stumbo et al., 2015; Varese et al., 
2012). In an examination of psychiatric inpatients, Schalinski and colleagues (2016) reported that 
89.8% met criteria for one or more ACEs, with an overall average of three childhood adversities 
and 37% exposed to at least four. Additionally, examining depression, dissociation, and PTSD 
symptom severity, researchers concluded that the factors most predictive of symptom severity 
were age of exposure (depression, dissociation, PTSD), duration of exposure (depression), 
overall severity of exposure (PTSD), and total number of childhood adversities to which a 
patient was exposed (PTSD and dissociation; Schalinski et al., 2016). 
Childhood Adversity and Offender Populations 
Evidence describing childhood adversity within forensic samples has primarily originated 
from juvenile and adult offender populations. Research demonstrates that childhood abuse and 
household dysfunction are more common among criminal offenders comparated to non-offenders 
(Levenson, 2013). In a study of juvenile offenders, Baglivio and colleagues (2015) found only a 
small percentage of adolescent male (3.1%) and female (1.8%) offenders reporting no ACEs, 
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while those who reported one experience of childhood adversity were more likely to report 
additional ACEs. Additionally, these juvenile offenders were four times more likely to have 
experienced four or more ACEs than those in the original ACE survey research that utilized 
community samples (Baglivio et al., 2015). Examining the effects of ACEs on psychiatric 
disorders in adolescent male offenders, Beilas and colleagues (2015) found that 91.5% of 
participants reported experiencing at least one ACE, and 75% reported two or more. In their 
study of chronic violent juvenile offenders, Fox and colleagues (2015) found that after 
controlling for criminal behavior and other risk factors, each additional adversity experienced as 
a child increased the risk of becoming a serious, violent, and chronic juvenile offender by 35 
percent.  
 Similar relationships are shown in adult offender populations. In one examination of 
childhood adversity, 30.7% of inmates reported exposure to four or more ACEs (Messina, 
Grella, Burdon, & Pendergast, 2007). Another study comparing four offender groups – 
nonsexual child abusers, sexual offenders, domestic violence offenders, and stalkers – reported 
that offender groups experienced nearly four times as many adverse events in childhood than the 
male normative sample, and that experiencing four or more events was reported at significantly 
higher levels among a criminal population (Reavis et al., 2013). In their study comparing male 
sexual offenders to a CDC community sample, Levenson, Willis, and Prescott (2014) found that 
nearly half of the offender sample reported at least four ACEs and were significantly more likely 
to endorse each of the ten ACE categories. 
 Female offenders exhibit results similar to their male offender counterparts. When 
compared to a female community sample, female sexual offenders were found to have reported 
experiencing no ACEs at significantly lower rates and being exposed to at least four adverse 
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events at significantly higher rates (Levenson, Willis, & Prescott, 2015). Additionally, Levenson 
and colleagues (2015) determined that female offenders were more likely to have experienced 
specific childhood adversities (e.g., three times more likely to have experienced emotional 
neglect, sexual abuse, and have household member incarcerated during childhood or 
adolescence) compared to females in a community sample. 
 Behavioral characteristics associated with offender populations (e.g., violence) and 
psychopathology, as well as their relationship to childhood adversity, have also been examined 
in offender populations. ACEs have been associated with reduced adaptability and increased 
social isolation, reduced self-esteem, and increased rates of dissociation and anger (Monnat & 
Chandler, 2015), as well as antisocial tendencies (Odgers et al., 2008). Among male adolescent 
offenders, cumulative ACE score is predictive of such psychopathology as PTSD, anxiety 
disorders, depressive disorders, and suicidality (Bielas et al., 2016). In a study investigating the 
relationship between adverse childhood events and types of aggressive behavior in adolescent 
males, Duke and colleagues (2010) found that for each ACE identified, there was an increased 
risk of violence among participants.  
The association between childhood adversity and violence has been examined in adult 
populations as well, demonstrating a clear link between violent behaviors and experiences of 
childhood adversity (CDC, 2016; Hilton, Ham, & Green, 2016). One study identified three 
specific adverse events (i.e., physical abuse, sexual abuse, household violence toward the 
mother) to be associated with the perpetration of intimate partner violence. Those males who 
experienced all three events were four times as likely to repeatedly engage in intimate partner 
violence as adults (Whitfield, Anda, Dube, & Felitti, 2003).  
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Childhood Adversity and Forensic Mental Health Populations 
Comparative to research examining offender and psychiatric populations, studies 
examining the prevalence of ACEs and their relationship to associated factors in forensic 
psychiatric inpatient samples are minimal. One study that examined six categories of adverse 
childhood experiences in a forensic mental health sample reported higher rates of adversity 
compared to a community sample, in which approximately three-fourths of patients reported 
experiences of at least one type of childhood maltreatment, just over half reported two or more, 
and nearly one-fifth reported four or more forms of childhood adversity (Stinson, Quinn, & 
Levenson, 2016).  
While little research has examined the prevalence and possible impact of cumulative 
ACEs in forensic psychiatric inpatient populations, some research has suggested high prevalence 
rates of specific childhood traumas. For example, Beck and colleagues (2017) reported that 
almost 90% of adult female forensic psychiatric inpatients classified as highly aggressive had 
experienced physical or sexual abuse as a child. Notably, individuals in this group had 
experienced the onset of psychiatric symptoms by the age of twelve (Beck et al., 2017). 
Dudeck and colleagues (2016) examined the relationship between ACEs, suicide 
attempts, and appetitive aggression, defined as perpetration of violence for the purpose of 
enjoyment, in 55 male forensic psychiatry inpatients. Results indicated that 34% of patients 
reported no ACEs, while 17% reported experiencing five or more adverse events in childhood. 
Additionally, these researchers reported ACEs as well as appetitive aggression to be predictors of 
suicidal behavior (Dudeck et al., 2016). 
In their study examining the impact of childhood adversity on mental illness and 
aggressive and criminal behaviors in 381 forensic mental health inpatients, Stinson and 
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colleagues (2016) reported that 92.4% of patients met criteria for at least two psychiatric 
disorders. Cumulative adversity scores were associated with younger ages of first arrest, 
psychiatric hospitalization, and onset of aggressive behavior. Additionally, 36.6% of patients had 
a history of attempting suicide, and 38.4% had a history of non-suicidal self-injurious behaviors. 
As cumulative adversity scores increased by one, patients were 22.4% more likely to have a 
combined history of suicide attempt and/or self-injurious behaviors. However, despite the 
strength of these relationships between ACEs and psychiatric and criminal outcomes, it was also 
noted that the addition of foster care placement diminished the predictive strength of the ACE 
score itself (Stinson et al., 2016).  
Intervention Practices in Forensic Mental Health Populations 
A significant focus of research examining forensic inpatient populations has been the use 
and effectiveness of varied interventions. In a systematic review (Tapp, Perkins, Warren, Fife-
Shaw, & Moore, 2013), researchers examined dietary, neurophysiological, psycho-educational, 
behavioral, psychological, and pharmacological interventions. The perhaps most commonly used 
interventions were pharmacological in nature. Examination of pharmacological interventions 
predominantly involves the use of antipsychotic medications for persons with treatment-resistant 
schizophrenia. While several studies provided evidence to support the use of antipsychotics and 
other medications to manage psychiatric symptoms as well as aggression, most had identifiable 
methodological restrictions that prevented a determination of treatment effectiveness (Tapp et 
al., 2013). 
 Because of the comparatively high prevalence rates of childhood adversity within 
forensic inpatient populations, it is likely that prominent psychiatric and behavioral symptoms 
are impacted by the presence of early trauma and maltreatment. Because mental health and 
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behavior management are a primary goal of forensic inpatient facilities, understanding 
medication practices and their relationship to specific behaviors, diagnoses, and precipitating 
factors is vital. Patients residing within forensic mental health inpatient facilities reportedly 
experience comparatively higher rates of childhood maltreatment and household dysfunction, 
thus potentially impacting the severity, prognosis, and age of onset of psychiatric symptoms. 
Higher rates of co-morbid and serious mental illness are found within this population. 
Pharmacotherapy has been identified as a primary treatment for serious mental illness (Tapp et 
al., 2013), and management of mental illness is frequently maintained through multiple 
prescriptions (Kukreja, Kalra, Shah, & Shrivastava, 2013). As such, these patients often receive 
multiple psychotropic medications as a primary treatment. It is necessary to gain a better 
understanding of medication practices, particularly polypharmacy, and the relationship to these 
diagnoses.   
Polypharmacy 
 Polypharmacy is defined within the empirical literature in varying ways, with the 
broadest definition referring to a single patient using multiple medications concurrently. 
However, even within this definition, the majority of research does not specify what qualifies as 
a “medication” beyond the generalized term of “drug,” or when discussing a specific drug or 
class of drugs (i.e., antipsychotic medications). One study included prescriptions, over the 
counter drugs, vitamins, and supplements under the umbrella definition of “medication” (Leahy, 
2017).  
 Polypharmacy has been defined quantitatively, qualitatively, and by the disease states for 
which prescriptions are given (i.e., psychotropic polypharmacy). Quantitatively it has been 
defined as ranging from two or more medications taken by one person (Cosano et al., 2016; 
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Dwyer, Han, Woodwell, & Rechtsteiner, 2010; Gniidic, Tinetti, & Allore, 2017; Guthrie, 
Makubate, Hernandez-Santiago, & Dreischulte, 2015; Haider, Johnell, Weitoft, Thorslund, & 
Fastborn, 2009; Janssen, Weinmann, Berger, & Gaebel, 2004; Jokanovic, Tan, Dooley, 
Kirkpatrick, & Bell, 2016; Jyrkka, Enlund, Korhonen, Sulkava, & Hartikainen, 2009; Leahy 
2017; Naples & Haiiar, 2016; Millan, 2014; Preskon & Lacey, 2007; Scott et al 2015; Viktil, 
Blix, Moger, & Reikvam, 2007; Vyas, Pan, Sambamoorthi, 2012). Others define polypharmacy 
qualitatively to include if a medication is prescribed without clinical indication, when an 
ineffective medication continues to be prescribed, if therapeutic duplication is present (Naples & 
Haiiar, 2016), and if a medication is used to treat a side effect or secondary symptom of another 
medication from a different drug class (de las Cuevas & Sans, 2005). 
 Polypharmacy within drug classes has been defined separately, with the most common 
definition referring to two or more medications of the same drug class being prescribed 
simultaneously (Cuevas & Sans, 2005; Londono et al., 2016). For example, psychotropic 
polypharmacy can refer to prescribing an anti-depressant and a mood stabilizer. More 
specifically, antipsychotic polypharmacy refers to the prescription of two or more antipsychotic 
medications (e.g., clozapine and olanzapine).  
Regardless of definition, the prevalence of polypharmacy continues to rise (Alpert, 2015). 
Increasing rates of polypharmacy are driven by a culture of single condition, guideline-driven 
prescribing practices and an increased prevalence of physical multimorbidity and psychological 
co-morbidity. Recent clinical guidelines have focused on the treatment of single conditions, 
which fail to account for these growing rates of multimorbidity (Moriarty, Hardy, Bennett, 
Smith, & Fahey, 2015). Additionally, professional guidelines recommend treatment of disease 
and illness with multiple drugs to achieve positive outcomes (Guthrie, Makubate, Hernandez-
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Santiago, & Dreischulte, 2015). And while polypharmacy drug regimens can have positive 
benefits, the practice may also result in severe negative consequences.  
Clinical Consequences of Polypharmacy 
Positive Consequences 
Polypharmacy often carries a negative connotation; however, in some cases it can be 
appropriate, such as when treating physical multimorbidity or serious mental illness. With regard 
to treating psychopathology and the potential benefit of polypharmacy, a great majority of the 
research has focused on psychotropic polypharmacy, though few studies evaluate psychotropic 
polypharmacy beyond antipsychotic polypharmacy. Most psychotropic polypharmacy research 
reports on the prevalence within populations with serious mental illness but seldom measure 
effectiveness. Peselow and colleagues (2016) compared pharmacological monotherapy 
management of bipolar disorder to polypharmacy management, with results indicating that 
patients experience greater symptom stability when pharmacotherapy management included two 
or more psychotropic medications. Some research supports the use of antipsychotic 
polypharmacy in treating those with schizophrenia resistant to monotherapy (e.g., Morrissette & 
Stahl, 2014). Additionally, antipsychotic polypharmacy has been proposed to mediate and 
decrease certain types of violence (e.g., Stahl, 2014); however, most antipsychotic polypharmacy 
research emphasizes the risk of polypharmacy and advises against its use. 
Negative Consequences 
The inherent complexity of treating co-morbid chronic illnesses and psychological 
disorders may be effectively addressed through polypharmacy; however, treatment must be 
carefully monitored due to the overwhelming conclusions of polypharmacy research that 
emphasize the negative clinical consequences of multiple drug regimens. The number of 
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medications a person is taking is the single most important predictor of harm (Scott et al., 2015). 
Each drug added to a patient’s medication regimen increases the likelihood of adverse outcomes 
(Preskorn & Lacey, 2007). The presence of one medication can alter the nature, magnitude, or 
duration of the effect of another medication by influencing the drug’s metabolism, absorption, 
and distribution within the body (Preskorn & Lacey, 2007). Polypharmacy has been consistently 
identified as a risk factor for increased adverse drug reactions, drug-drug interactions, cost of 
care, medication regimen nonadherence, inappropriate prescribing, functional impairment, 
morbidity, mortality, and, specific to antipsychotic polypharmacy, extrapyramidal side effects. 
Studies show an association between the number of medications a person is taking and linear 
increases in negative health outcomes (Fried, O’Leary, Towle, Goldstein, Trentalange, & Martin, 
2014), even when only by one medication (Leahy, 2017). Factors particularly relevant to forensic 
inpatient populations, many of whom may require complex medication regimens, will be 
described below. 
Adverse drug reactions. Drug-related problems and adverse drug events are regularly 
reported as direct consequence of polypharmacy practices (Viktil et al., 2006). An adverse drug 
event (ADE) is defined as injury resulting from medication (Naples & Hajjar, 2016) that includes 
adverse drug reactions, medication errors, allergic reactions, and drug overdoses. ADEs are 
becoming increasingly common and account for a significant percentage of healthcare utilization 
(ODPHP, 2017). ADEs have become larger contributors to outpatient and emergency room visits 
(Burgess, Holman, & Satti, 2005) and as the primary cause for hospitalization (Bourgeois, 
Shannon, Valim, & Mandl, 2010).  
Adverse drug reactions (ADR), defined as noxious and unintended responses that occur 
at a normal dose of medication, are the most common type of ADE (Naples & Hajjar, 2016). As 
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the number of medications taken increases, the risk of ADRs increases (Leahy, 2017). For 
example, outpatients had an 88% higher risk of ADRs when taking five or more medications 
(Bourgeois et al., 2010). Similarly, compared to those taking fewer medications, hospitalized 
older adults taking five or six medications or those taking seven or more medications were two 
and four times as likely to experience an ADR, respectively (Onder et al., 2010). 
The most common complications resulting from ADRs include gastrointestinal 
complications, metabolic and hemorrhagic complications, and sedation (Armstrong & 
Temmingh, 2017; Barnes & Paton, 2011; Medeiros-Souza, dos Santos-Neto, Kusano, & Pereira, 
2007). The consequences of ADRs can be severe, potentially leading to hospitalization and even 
death (Medeiros-Souza et al., 2007; Naples & Hajjar, 2016). In their population-based analysis 
of changes in polypharmacy and related interactions, Guthrie and colleagues (2015) identified 
cardiovascular, central nervous system, gastrointestinal, and endocrine drug classes as seeing the 
largest absolute rise. Many drugs most commonly associated with ADRs, including 
cardiovascular drugs, diuretics, nonsteroidal anti-inflammatory drugs, agents to address diabetes, 
anticoagulants, antibiotics, anticonvulsants, and antipsychotics are classified in these groups 
(Medeiros-Souza et al., 2007; Naples & Hajjar, 2016). Still, the two drug classes most commonly 
associated with negative side effects are cardiovascular drugs and those specific to the central 
nervous system, like benzodiazepines (Medeiros-Souza et al., 2007).  
Drug-drug interactions. Polypharmacy is associated with higher rates of drug-drug 
interactions (DDIs; Guthrie et al., 2015). DDIs occur when two or more drugs react with one 
another. These interactions may increase or decrease the effectiveness of a medication or cause 
negative side effects, such as sedation (Food and Drug Administration, 2016). These interactions 
are a frequent cause of preventable ADEs (Naples & Hajjir, 2016).  
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As the number of drugs prescribed increases, the likelihood for potentially serious DDIs 
escalates. For example, the proportion of people with potentially serious DDIs was 80.8% among 
those prescribed 15 or more medications, compared to 10.9% of those prescribed 2 to 4 
medications (Guthrie et al., 2015). Similarly, in a study of older adults, it was determined that the 
probability of DDIs increased 50% when prescribed five to nine medications and 100% when 20 
or more medications were prescribed (Doan, Zakrewski-Jakubiak, Roy, Turgeon, & 
Tannenbaum, 2013). Additionally, the proportion of the population at risk for serious DDIs more 
than triples, regardless of age group, because of polypharmacy (Guthrie et al., 2015).  
Cost of care. Each drug added to a medication regimen not only increases the likelihood 
of adverse outcomes but also the expense of treatment (Preskorn & Lacey, 2007). Inappropriate 
polypharmacy has high associated costs for patients, insurance companies, and the government 
(Anda, Brown, Felitti, Bremner, Dube, & Giles, 2007; Viktil et al., 2006). Increased costs are 
attributable to increased cost of prescriptions, new drug development, and increases in 
prescribing practices (Medeiros-Souza et al., 2007). The latter factor not only increases cost due 
to the number of prescriptions but also because of the increased costs associated with the higher 
risk of ADEs. 
 In a study of antipsychotic polypharmacy among 246 state hospital male inpatients, 
Lacassee (2014) demonstrated an association between antipsychotic polypharmacy and length of 
stay. Interestingly, a majority of patients were either admitted already on or subsequently given 
antipsychotic polypharmacy regimens (Lacassee, 2014). Researchers insist that antipsychotic 
polypharmacy not only tends to result in high dosing (Gallego, Bonetti, Zhang, Kane, & Correll, 
2012), but it also impairs functional recovery (Wunderlink, Nieboer, Wiersma, Sytema, & 
Nienhuis, 2013) and can lead to extended hospitalization (Lacassee, 2014).  
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Extrapyramidal side effects. Potentially serious adverse effects can stem from first 
generation antipsychotic and antipsychotic polypharmacy prescriptions (Armstrong & 
Temmingh, 2017). In a population-based study, Carnahan and colleagues (2006) reported that 
compared to patients receiving antipsychotic monotherapy, those receiving antipsychotic 
polypharmacy were at an increased risk of being prescribed medications meant to treat 
extrapyramidal side effects. These extrapyramidal side effects, or drug induced movement 
disorders, include dystonia, akathisia, Parkinsonism, and tardive dyskinesia (Buckley, Citrome, 
Nichita, & Vitacco, 2011; Pierre, 2005).  
These types of side effects often discourage patient willingness to maintain prescribed 
medication regimens, not only because of the related symptoms but also because many 
medications prescribed to counteract extrapyramidal side effects have negative side effects of 
their own (Carnahan, Lund, Perry, & Chrischilles, 2006). The most commonly recommended 
medications to treat extrapyramidal side effects are anticholinergics, less commonly, dopamine 
agonists. (Pringsheim, Doja, Belanger, & Patten, 2011). Because atypical antipsychotics have 
varying degrees of anticholinergic effects, adding an anticholinergic drug yields a potential for 
serious side effects that cause physical and mental deterioration, which can significantly impair 
overall functioning. Potential side effects may include sedation, memory impairment, 
constipation, blurry vision, and confusion (Lieberman, 2004), with a majority of research 
investigating effects of anticholingeric drugs linking cognitive impairment and eventual 
dementia (Campbell et al., 2009).  
Mortality. Polypharmacy has been associated with an increased risk of mortality 
(Lacassee, 2014). Research indicating increased mortality as a consequence of polypharmacy 
largely focuses on older adult populations and patients taking multiple antipsychotic 
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medications. For example, in one study of older adults in Spain, polypharmacy of six or more 
medications was associated with a nearly two-fold increase in mortality risk (Gomez, Vega, 
Bermejo-Pareja, Medrano, Louis, & Benito-Leon, 2014). In a review of antipsychotic 
polypharmacy, Langan and Shajahan (2010) concluded that antipsychotic polypharmacy is an 
increasing concern due to evidence that the more antipsychotics given concurrently, the shorter a 
patient’s lifespan (e.g., Waddington, Yousseff, & Kinsella, 1998). Additionally, one study 
reported a graded relationship between mortality and the number of neuroleptics prescribed, 
noting that those prescribed three antipsychotics were twice as likely to die than those prescribed 
only one (Joukamaa, Heliovaara, Knekt, Aromaa, Raitasalo, & Lehtinen, 2006). Generally, 
research has indicated that mortality is not dependent on average daily dose or total lifetime dose 
of antipsychotic medications, but rather the maximum number of antipsychotic medications a 
patient takes concurrently (NASMHPD, 2001). 
Polypharmacy and ACEs 
The available literature suggests a relationship between ACEs and prescription practices. 
Using data from the original ACE study, Anda and colleagues (2007) found a graded relationship 
between total ACE score, prescription rates, and prescribing more serious classes of medications, 
including antidepressants, anxiolytics, antipsychotics, and mood stabilizers. Bjorkenstam and 
colleagues (2013) reported a similar relationship of increased risk of psychotropic medication 
use for Swedish participants as their reported ACEs increased. Koskenvuo and Koskenvuo 
(2014) reported a graded linear relationship between ACEs and psychotropic medication 
purchase in a Finnish population, with individuals reporting five to six childhood adversities 
more likely to use psychotropic medications than those who experienced fewer or no adversities. 
Additionally, those who had experienced conflict within their family during childhood were 
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twice as likely to use multiple antipsychotics, mood stabilizers, antidepressants, anxiolytics, 
hypnotics, and sedatives (Koskenvuo & Koskenvuo, 2014). 
Although research related to ACEs and polypharmacy is minimal, several studies have 
focused on the relationship of polypharmacy to other factors associated with ACEs, including 
lower socioeconomic status and serious mental illness. Individuals in lower socioeconomic 
groups often experience physical multimorbidity and psychological co-morbidity and, on 
average, experience negative health outcomes ten to fifteen years earlier than more economically 
advantaged populations (Guthrie et al., 2015). In their population database analysis examining 
how the prevalence of polypharmacy changed between 1995 and 2010, Guthrie and colleagues 
(2015) demonstrated that people living in more deprived areas were more than twice as likely to 
be prescribed ten or more drugs, even after controlling for age and residence in long-term care 
facilities. 
Polypharmacy and Forensic Mental Health Populations 
 Given the rates of ACEs in forensic and inpatient mental health populations, it is not 
surprising that mental illness and psychotropic medication use are prevalent as well. In a review 
of polypharmacy in psychiatry, Moller and colleagues (2014) reported similarities in the 
prevalence of polypharmacy among patients in university hospitals, state hospitals, and inpatient 
psychiatry wings of general hospitals. For example, one study reported no significant difference 
in the rates of polypharmacy for outpatient (52.1%) and inpatient (44.3%) populations (Karadag, 
Orsel, & Turkcapar, 2012). Across settings, polypharmacy is increasing, most notably in 
psychiatric medicine where the occurrence of prescribing more than four psychotropic 
medications per person has significantly increased in the last two decades (Moller et al., 2014). 
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 Rates of psychotropic polypharmacy differ with regard to treatment of specific 
psychiatric disorders. In a review of polypharmacy trends associated with bipolar disorder, 
Fornaro and colleagues (2016) reported psychotropic polypharmacy rates as high as 85%, noting 
specific antidepressant polypharmacy rates of 45% and antipsychotic polypharmacy rates of 
80%. In fact, the most significant increases in psychotropic polypharmacy are associated with 
antidepressant and antipsychotic medication use (Karadag et al., 2012; Moller et al., 2014).  
Despite the widespread practice of antipsychotic polypharmacy in inpatient settings, there 
is little evidence to support the effectiveness of this practice in addressing schizophrenia-related 
symptoms in comparison with monotherapy (Mace & Taylor, 2015). Beyond treatment of 
psychotic symptoms, antipsychotics are also often used to manage actual or perceived violent 
behavior in those with psychosis, particularly within inpatient forensic settings (Swanson et al., 
2008). One study found that while severity of symptoms was similar between male and female 
inpatients, being male was predictive of antipsychotic polypharmacy (Lacassee, 2014). Lacasse 
(2014) also concluded that among males who had been previously committed for forensic 
reasons, their status as forensic referrals may have elicited perceived dangerousness and thus 
influenced physician prescription practices. Research suggests that using antipsychotic 
medications for treatment of aggression should be limited due to the risk of serious side effects 
(Krakowski, 2008; Morrissette & Stahl, 2014; Suokas, Suvisaari, Haukka, Korhonen, & 
Tiihonen, 2013). Other medications often used to treat violent behaviors with some effectiveness 
include mood stabilizers, beta-blockers, and antidepressants; however, each of these has only 
been reported as effective in certain populations, and each carries contraindications for its use 
(e.g., beta-blockers should not be used in patients with cardiovascular disease, asthma, or 
diabetes; Krakowski, 2008).  
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Beyond aggression and violent behaviors, another common concern within inpatient 
settings is suicidal behavior. In psychiatric hospitals, individuals with suicidal ideation and 
suicide attempts (Fontanella, Bridge, & Campo, 2009), as well as impulsivity and self-harm 
behaviors, are frequently treated with psychotropic polypharmacy medication regimens (Madan, 
Oldham, Gonzalez, & Fowler, 2015). In a study examining the effectiveness of pharmacological 
interventions for adolescent inpatients with suicidal ideation and behaviors, Fontanella and 
colleagues (2009) reported the additions of at least one antidepressant, mood stabilizer, or 
antipsychotic medication in 78% of suicidal patients. Results indicated that treatment with an 
antidepressant at discharge was associated with a lower risk of hospital readmission, while being 
discharged with three or more medications of different drug classes was associated with a 2.6 
times greater risk of readmission (Fontanella et al., 2009).  
Study Overview 
While a definitive association between ACEs and negative outcomes has been 
established, particularly in community samples, little research has examined the relationship 
between ACEs, related negative outcomes, and psychotropic prescription practices in forensic 
mental health populations, who experience markedly increased ACEs, serious psychopathology, 
and polypharmacy. 
This study will use a subset of existing data collected within the context of a larger study 
to address gaps in the literature and achieve the following aims: 
• Establish patterns of polypharmacy use across varying diagnostic presentations and with 
a degree of diagnostic comorbidity; 
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• Identify relationships between ACEs, demographic factors, aggression, and 
suicidality/self-harm in forensic mental health patients receiving multiple medications; 
and 
• Examine the impact of these factors on polypharmacy practices, including medical and 
psychotropic polypharmacy. 
In order to meet these aims, eight hypotheses will be tested: 
1. Patients with more mental health diagnoses will exhibit a greater degree of psychotropic 
polypharmacy. 
2. Patients with serious mental illness diagnoses will exhibit a greater degree of 
polypharmacy. 
3. Patients with longer length of hospitalization will evidence greater polypharmacy. 
4. Regardless of diagnosis, higher ACEs will be predictive of greater polypharmacy use. 
5. Demographic factors, including age, gender, and race/ethnicity, will affect polypharmacy 
use. 
6. Patients with a history of ACEs and that have prior histories of self-harm, suicide 
attempts, institutional aggression, or lengthier occurrences of psychiatric hospitalization 
will be prescribed a greater number of psychotropic medications.   
7. Patients with a history of ACEs and that have prior histories of self-harm, suicide 
attempts, institutional aggression, or lengthier occurrences of psychiatric hospitalization 
will experience greater antipsychotic and mood-stabilizing polypharmacy.  
8. Higher rates of polypharmacy will yield a greater number of medications prescribed to 






Setting and Sample 
The current study will use archival data collected from a larger study of ACEs in forensic 
mental health inpatients residing in a maximum- and intermediate-security forensic hospital in 
the Midwestern U.S. The research team for this study included a forensic clinical psychologist, 
an epidemiologist, and trained undergraduate and graduate research assistants. 
Data were collected from 2013-2014. Participants were patients admitted to the facility 
following acts of aggression in the community or other, less secure facilities, and whose charges 
had subsequently been dropped. Inclusion criteria for participant eligibility included admission to 
the facility after 2005, discharge prior to data collection, and facility residence of at least one 
year. Data from a total of 182 residents were obtained. The records of each were reviewed and 
included within the larger dataset.  All procedures were approved by the ETSU Medical IRB and 
the Research Review Committee of the participating institution and state Department of Mental 
Health. Data collection was funded by East Tennessee State University through a Research 
Development Committee Major Grant.  
Terms 
Polypharmacy 
In the current study, polypharmacy is defined as the concurrent prescription of five or 
more medications. While the literature gives no universally agreed upon or definitive definition 
of polypharmacy, research has demonstrated that using more than four medications represents an 
increased potential risk for the occurrence of drug related problems, increased poor health 
outcomes, and, in many cases, does not improve the clinical efficacy of treatment (Viktil et al., 
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2006). Psychotropic polypharmacy will be defined as the use of two or more psychotropic 
medications concurrently. While definitions within the literature vary from the concurrent use of 
two to four medications, the most commonly used definition is two or more (Londono et al., 
2016).  
Measures 
Adverse Childhood Experiences (ACE) Survey  
Participants’ ACE scores were determined from review of patient medical records. The 
ACE survey (Felitti et al., 1998) is a ten-item measure assessing exposure to various adversities 
in childhood. Specific adversities measured include emotional abuse, physical abuse, sexual 
abuse, emotional neglect, physical neglect, parental separation or divorce, domestic violence in 
the household, incarceration of a household member, household substance abuse, and mental 
illness in the household, all prior to the participant reaching the age of 18. Each ACE item was 
coded as either present (1) or absent (0), and the ACE score was determined by summing each of 
the 10 ACE items. 
Procedure 
            Once participant selection was complete, trained research assistants reviewed archival 
data from each participant’s chart including medical, psychiatric, and social service records, 
family reports, annual review reports, and discharge summaries. Psychiatric diagnoses were 
categorized using the DSM-IV-TR diagnostic codes. Diagnoses were collapsed into categories 
that included mood disorder, psychotic disorder, impulse related disorder, anxiety disorder, 
attention deficit hyperactivity disorder, sexual disorder, intellectual and developmental disability, 
and specific personality disorders.  For example, diagnoses with a mood specifier (e.g., 
depression, bipolar disorder) were categorized as mood disorders. The presence of a diagnosis 
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was coded dichotomously as absent or present. This permitted co-morbidity and diagnostic 
variability among mental health evaluators (e.g., schizoaffective disorder vs. co-morbid 
schizophrenia and depression). A history of attempted suicide and self-harm behaviors were 
dichotomously recorded as absent or present. Aggression was determined through a recorded 
history of aggression within the community or within any previous or the current institutional 
setting. Each of these variables were coded dichotomously as absent or present. Prescribed 
psychotropic medications were categorized by the disease condition they are approved to treat 
(e.g., antidepressant) and also dichotomously coded as absent or present. 
Statistical Analysis Plan 
Hypothesis 1 
Patients with more mental health diagnoses will exhibit a greater degree of psychotropic 
polypharmacy.	  Diagnostic presentation was examined by number of diagnostic categories (e.g., 
mood disorder, psychotic disorder, anxiety disorder). Polypharmacy was examined in three 
ways: overall polypharmacy coded dichotomously (no polypharmacy versus polypharmacy), 
number of medications prescribed, and incidence of polypharmacy of specific classes of drugs 
(dichotomously coded).	  
 To assess the relationship between diagnostic presentation and polypharmacy use, 
logistic and Poisson regressions were used. Specifically, logistic regression was used to examine 
the relationship between diagnostic variable and presence of any type of polypharmacy, as well 
as between diagnostic variable and specific classes of drugs. Poisson regression analysis was 





Patients with serious mental illness diagnoses will exhibit a greater degree of 
polypharmacy. Serious mental illness (SMI), as defined by a diagnosis of a bipolar or psychotic-
spectrum disorder, was examined dichotomously (i.e., diagnosis of at least one SMI versus no 
SMI diagnosis). Polypharmacy was examined in three ways: overall psychotropic polypharmacy 
coded dichotomously (no polypharmacy versus polypharmacy), number of medications 
prescribed, and incidence of polypharmacy for specific classes of drugs (dichotomously coded). 
Poisson and logistic regression analyses were employed to examine these relationships. 
Specifically, Poisson regression was used to examine the association between SMI and number 
of medications. Logistic regression analyses were used to examine the relationships between 
SMI and the presence of types of polypharmacy (psychotropic, mood stabilizer, antipsychotic).  
Hypothesis 3 
Patients with longer length of hospitalization will evidence greater polypharmacy. 
Length of hospitalization was determined by comparing admission and discharge dates.  
Poisson regression was used to examine the association between length of hospitalization and 
number of prescribed medications. Logistic regression analyses were used to examine the 
relationship between length of hospitalization and the presence of each identified type of 
polypharmacy (psychotropic, mood stabilizer, antipsychotic). 
Hypothesis 4 
Regardless of diagnosis, higher ACEs will be predictive of greater polypharmacy use. 
Diagnostic presentation was examined by number of diagnostic categories identified within 
participants’ medical records. ACE score were examined in two ways: total ACE score and ACE 
score of four or more, coded dichotomously (i.e., less than four ACEs versus four or more 
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ACEs). Poisson regression was used to examine relationships between ACE variables and 
number of mental illness diagnostic categories. Additionally, Poisson and logistic regression 
analyses were used to examine the relationship between ACE variables and psychotropic 
polypharmacy practice, as defined previously.  
Hypothesis 5 
Demographic factors, including age, gender, and race/ethnicity, will affect polypharmacy 
use. Exploratory analyses, including correlations and chi-squares, were used to examine 
relationships between polypharmacy practices, age, gender (male and female), and race/ethnicity 
(white and non-white). Gender and race were coded as dummy variables. If significant 
relationships were identified those relationships were examined with linear regression analysis.  
Hypotheses 6 and 7  
Patients with prior histories of self-harm, suicide attempts, institutional aggression, or 
lengthier occurrences of psychiatric hospitalization will be prescribed a greater number of 
psychotropic medications.  Additionally, patients with prior histories of self-harm, suicide 
attempts, institutional aggression, or lengthier occurrences of psychiatric hospitalization will 
experience greater antipsychotic and mood-stabilizing polypharmacy. To examine the impact of 
ACEs, aggression, suicidality/self-harm behaviors, and history of psychiatric hospitalization on 
varying types of polypharmacy practices, regression and mediation analyses were conducted. To 
assess the relationship between experiences of childhood adversity and polypharmacy, the 
impact of ACE scores on number of medications were examined using linear regression 
analyses. Two linear regression analyses were used to assess the relationship between cumulative 
ACE score and degree of overall polypharmacy and degree of psychotropic polypharmacy. 
Logistic regression analyses were used to examine the relationship between cumulative ACE 
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score and types of psychotropic polypharmacy (i.e., antipsychotic, mood stabilizer, 
antidepressant polypharmacy).	  
The relationship between aggression, suicidality, and self-harm behaviors with 
polypharmacy were examined with three logistic regression and three linear regression analyses 
examining the impact of aggression, suicidality (operationally defined as history of suicide 
attempts and dichotomously coded as no history versus history), and self-harm behaviors 
(defined as history of self-harm, dichotomously coded) on polypharmacy practices (i.e., defined 
as psychotropic polypharmacy, dichotomously coded) and on the degree of psychotropic 
polypharmacy (i.e., number of psychotropic medications prescribed). To assess the relationship 
between history of psychiatric hospitalization and polypharmacy practices, linear and logistic 
regressions were used. Specifically, logistic regression was used to examine the relationship 
between history of psychiatric hospitalization (defined by number of previous hospitalizations) 
and if a patient is or is not on a psychotropic polypharmacy regimen. Linear regression analysis 
was used to determine if history of psychiatric hospitalization is predictive of the number of 
psychotropic medications prescribed.  
Mediating pathways were additionally examined. Age, gender, and race served as 
covariates; total ACE score and an ACE score of four or more served as the independent 
variables; and aggression, suicidality, self-harm behaviors, and history of psychiatric 
hospitalization served as mediators. Mediation analyses were conducted, with dependent 
variables that included number of psychotropic medications, presence of psychotropic 
polypharmacy, presence of polypharmacy with mood stabilizers, and presence of antipsychotic 
polypharmacy.  
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Baron and Kenny (1986) have proposed investigating mediation through a series of three 
simple regression models (Figure 1). This process is particularly relevant for examining 
mediating relationships with a dichotomous mediator and/or dependent variables. Step one is to 
establish a significant relationship between the independent and dependent variables (i.e., 
significant total effect, path c). Step two is to establish a significant relationship between the 
independent variable and the mediator (i.e., path a). Step 3 is a multiple regression model to 
establish a significant relationship between the mediator and dependent variable (i.e., path b) 
while the independent variable is controlled. Step 4 is to establish if the mediator fully or 
partially mediates the effect of the independent variable on the dependent variable (i.e., 
significant direct effect, path c’). Full mediation is indicated if a significant relationship between 
the independent and dependent variables is eliminated when the mediator is controlled. Partial 
mediation is indicated when the significant relationship between the independent and dependent 
variables is reduced but not fully eliminated (Baron & Kenny, 1986).  
To rescale the logistic regression predictor and mediator coefficients to make them 
comparable across equations, each was multiplied by the standard deviation of the predictor 
variable and then divided by the standard deviation of the outcome variable (Kenny, 2013). The 
binomial variance was estimated with π/3 (Kenny, 2013; Newsom, 2016). To determine if the 
mediation effect is statistically significant, a bootstrapping approach was implemented (Adjei & 






Figure 1. Mediation analysis model (Baron & Kenny, 1986).  
 
Hypothesis 8 
Higher rates of polypharmacy will yield a greater number of medications prescribed to 
address pharmacological side effects. The relationship between polypharmacy (independent 
variable) and number of medications prescribed to treat side effects resulting from polypharmacy 
(dependent variable) was examined using linear regression analysis. 	  











 Of the 182 participants, 80.8% were male (n = 147). The majority were Caucasian 
(55.5%; n = 101) or African American (40.1%; n = 73), with the remainder self-identified as 
Hispanic, Asian, Native American, or unknown/mixed race (4.3%; n = 8). The average age at 
time of admission to the facility was 32.5 years (SD = 11.6 years), with a mean age at discharge 
of 40.5 years (SD = 12.7 years).  
Adverse Childhood Experiences 
 A majority of participants were exposed to childhood adversity (75.8%; n = 138), with an 
average ACE score of 2.63 (SD = 2.3). Of the total sample, 25.6% were exposed to four or more 
ACEs (n = 47). Total cumulative ACE scores are described in Table 1. Childhood abuse and 
neglect were prevalent within the sample, with reported rates as follows: physical abuse (35.7%; 
n = 65), sexual abuse (33.0%; n = 60), emotional abuse (24.2%; n = 44), and neglect (17.6%; n = 
32). Nearly one-fifth of participants witnessed domestic violence toward a parent in their home 
(19.2%; n = 35). Over one-third of participants’ parents were divorced or separated during their 
childhood (35.7%; n = 65), and 5.5% had a parent or guardian incarcerated (n = 10). Just over 
one-fourth of the sample reported one or both parents to have suffered with at least one mental 
illness (25.3%; n = 46), and 32.4% reported a parent with known substance abuse during their 






ACE Score (N = 182) 
ACE Score n (%) 
0 44 (24.2) 
1 41 (22.5) 
2 32 (17.6) 
3 18 (9.9) 
4 9 (4.9) 
5 21 (11.5) 
6 7 (3.8) 
7 7 (3.8) 
8 2 (1.1) 
9 1 (0.5) 
10 0 (0.0) 
 
Clinical Functioning 
 As expected from participants’ current admission to secure forensic inpatient care, 
psychiatric diagnoses were common. Descriptions of DSM-IV-TR (American Psychological 
Association, 2000) diagnostic categories are listed in Table 2. Participants were diagnosed with 
an average of 3.37 mental health symptom categories (SD = 1.65). Axis I disorders were 
diagnosed in 98.9% (n = 180) of the total sample. Psychotic and mood disorders were the most 
common Axis I disorders. Additional variables describing psychiatric functioning were 
examined. Of the total participants, 41.8% had a reported history of at least one suicide attempt 
(n = 76). Approximately 46% of participants had a history of self-injurious behavior (n = 83). A 
majority of participants exhibited a history of institutional aggression (86.8%; n = 158). Average 
length of admission was 8.01 years (SD = 7.11), with an average of 14.78 (SD = 12.27) separate 






 Frequency of Psychiatric Disorders (N=182) 
Psychiatric Disorder n (%) 
Mood Disorders 83 (45.6) 
Anxiety Disorders 16 (8.8) 
Post-Traumatic Stress Disorder 24 (13.2) 
Psychotic Disorders 109 (59.9) 
Attention Deficit Hyperactivity Disorder 18 (9.9) 
Impulse Disorders 41 (22.5) 
Intellectual Disability / Cognitive / 
Developmental Disorders 
105 (57.7) 
Sexual Disorders 12 (6.6) 
Anti-Social Personality Disorder 14 (7.7) 
Borderline Personality Disorder 11 (6.0) 




 Within the total sample of 182 participants, 131 participants’ were prescribed 
psychotropic medications. Of these 131 participants, nearly all were prescribed at least two 
psychotropic medications (n = 129; 98.5%) with a mean number of psychotropic medications of 
5.23 (SD = 2.20) and a range of zero to thirteen total different psychotropic medications 
prescribed to a given individual. Frequencies of psychotropic medication prescription, by 
number of medications, are provided in Table 3. A majority of patients were prescribed at least 
four different categories of psychotropic medications (n = 100; 75.7%) with a mean of 
approximately four different categories of psychotropic medications being prescribed to patients 
(M = 3.99, SD = 1.12).  Significantly more individuals were prescribed four or more 
prescriptions than not (t = 27.162, p < 0.001). The most common types of medications include 
those with an on-label use of addressing mood (n = 121; 92.4%), psychotic (n = 117; 89.3%) and 
anxiety (n = 112; 85.5%) symptom concerns. Patients were prescribed an average of 2.30 (SD = 
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1.29) mood stabilizers, 2.17 (SD = 1.73) anxiolytics, and 1.71 (SD = 0.98) antipsychotic 
medications. 
Table 3 
Frequency of Number of Psychotropic Medications 
Number of Psychotropic 
Medications 
n (%) 
0 2 (1.1) 
1 0 (0.0) 
2 11 (8.4) 
3 11 (8.4) 
4 28 (21.4) 
5 26 (19.8) 
6 19 (14.5) 
7 17 (13.0) 
8 10 (7.6) 
9 1 (0.8) 
10 or more 6 (4.7) 
 
 
Clinical Functioning and Prescription Practices 
Hypothesis 1 
Patients with more mental health diagnoses will exhibit a greater degree of psychotropic 
polypharmacy. Poisson and logistic regression analyses were used to assess the relationship 
between number of mental health diagnostic categories and prescription practices. All analyses 
controlled for age, gender, and race. Gender (male and female) and race (white and non-white) 
were coded as dummy variables.  
 To examine the relationship between mental health and psychotropic prescription 
practices, the relationship between total number of mental health diagnostic categories and 
prescription practices of the total sample of 182 participants was evaluated. A significant Poisson 
regression model predicting psychotropic prescription practices emerged, with higher mental 
health disorder diagnoses being predictive of higher numbers of prescription medications (Table 
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4). That is, for every additional mental health diagnostic category, 1.055 (95% CI [1.012 to 
1.100]) psychotropic prescriptions were given (p = 0.013). More specifically, the model was 
significant for prescriptions of mood-stabilizing medications, indicating that regardless of a 
diagnosed mood disorder, with each mental health diagnosis an additional 1.098 (95% CI [0.873 
to 1.445]) mood-stabilizers were prescribed (p = 0.016).  
 Logistic regression analysis produced a significant model describing the effects of mental 
health disorder diagnosis on psychotropic polypharmacy (χ2 = 5.772, Nagelkerke’s R2 = 0.098, p 
= 0.016). Specifically, increases in mental health disorder diagnoses were associated with 
increased likelihood of psychotropic polypharmacy (OR = 1.407; 95% CI [0.975, 1.798]; Table 
4). Models examining the association between mental health disorder diagnosis and 
antipsychotic polypharmacy and mood-stabilizer polypharmacy were not significant.  
Table 4 
Mental Health Disorder Effect on Psychotropic Prescription Practices 
 B SE Wald χ2 p Exp(B) 
# Psychotropic Medications .053 .021 6.227 .013 1.055 
Psychotropic Polypharmacy .342 .151 5.101 .024 1.407 
 
Hypothesis 2 
Patients with serious mental illness diagnoses will exhibit a greater degree of 
polypharmacy. Poisson and logistic regression analyses were used to examine the relationship of 
diagnosed serious mental illness and psychotropic prescription practices (Table 5). While a 
diagnosis of at least one serious mental illness was not predictive of increased numbers of 
psychotropic prescriptions nor psychotropic polypharmacy, results indicate a significant 
relationship with antipsychotic polypharmacy (χ2 = 5.334, Nagelkerke’s R2 = 0.054, p = 0.021). 
The model correctly classified 64.1% of cases. Participants diagnosed with a serious mental 
47 
illness were 2.747 times more likely to be subject to antipsychotic polypharmacy than those 
without a serious mental illness.  
Table 5 
Serious Mental Illness and Psychotropic Prescription Practices 
 B SE Wald χ2 p Exp(B) 
# Psychotropic Medications .727 .790 .845 .358 2.068 
Psychotropic Polypharmacy -.705 .659 1.144 .285 .494 
 
Hypothesis 3 
Patients with longer length of hospitalization will evidence greater polypharmacy. 
Length of hospitalization was not significantly related to psychotropic polypharmacy 
prescription practices (Table 6).  
Table 6 
Correlational Relationships Between ACE Score Variables, Behavioral Markers, and 
Psychotropic Medication Practices 









Hx Self-harm .386** .262** .218* .280** 
Hx Suicide Attempts .141 .086   .095 .032 
Hx Institutional Aggression .119 .084 .284* .241** 
# Previous Psychiatric 
Admissions .102 .207* .192* .133 
Length of Admission .115 .126 .106 .094 
*p<.05, **p<.01, ***p<.001  
 
Hypothesis 4 
Regardless of diagnosis, higher ACEs will be predictive of greater polypharmacy use. A 
significant model relating total cumulative ACE score to number of mental health symptom 
categories and prescription practices emerged (Table 7). Total ACE score was predictive of total 
mental health diagnoses (1.078, 95% CI [1.042, 1.116], p<0.001). Total number of mental health 
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diagnostic categories was thus controlled for in further analyses. Poisson regression produced a 
model predictive of a higher number of psychotropic prescriptions, with an increase of one on 
the total ACE score yielding a predicted increase of medications by 1.075 (95% CI [1.007, 
1.147], p = 0.030). An increase in total ACE score was associated with increased risk of 
psychotropic polypharmacy (OR = 1.313; p=0.035). 
Table 7 
Regression Analyses of Total ACE Score to Psychotropic Polypharmacy Practices 
 B SE Wald χ2 p Exp(B) 
# Psychotropic Medications .072 .0331 4.729 .030 1.075 
Psychotropic Polypharmacy .273 .130 4.426 .035 1.313 
 
An evaluation of the average number of psychotropic prescriptions per each increase in 
ACE score was completed (Figure 2). A graded relationship between ACE score and 
prescriptions was observed. Models examining the association between total ACE score, total 
number of types of psychotropic medications, total number mood stabilizers, and total number of 
antipsychotic medications were not significant.   
 














Total ACE Score 
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Participants with an ACE score of four or higher were prescribed significantly more 
psychotropic medications (F = 5.079, R2 = 0.038, p = 0.026). Interestingly, those with four or 
more ACEs were 5.123 (p = 0.033) times more likely to experience psychotropic polypharmacy 
than those with fewer than four ACEs (χ2 = 6.498, Nagelkerke’s R2 = 0.079, p = 0.011; Table 8). 
Additionally, participants with four or more ACEs were 3.362 (p = 0.041) times more likely to 
be prescribed an antipsychotic medication regardless of being diagnosed with a serious mental 
illness (χ2 = 3.947, Nagelkerke’s R2 = 0.042, p = 0.047).  
Table 8 
Regression Analyses of 4+ ACE Scores to Psychotropic Polypharmacy Practices 
 B SE Wald χ2 p Exp(B) 
# Psychotropic Medications 1.120 .253 4.271 .026 2.254 
Psychotropic Polypharmacy 1.634 .767 4.535 .033 5.123 
 
Hypothesis 5 
Demographic factors, including age, gender, and race/ethnicity, will affect polypharmacy 
use. Linear regression analysis produced a significant model (Table 9) predicting earlier age of 
being prescribed a psychotropic medication as related to white ethnicity (F = 4.658, R2 = 0.115, 
p = 0.038). White participants were prescribed their first psychotropic medication, on average, 
during adolescence (M = 13.47, SD = 9.58, range = 4-43), while non-white participants were 
prescribed their first psychotropic medication in adulthood (M = 20.26, SD = 9.81, range = 9-49).  
Table 9 
White Ethnicity Predictive of Earlier Age Prescribed Psychotropic Medications 
 B SE β t p 
Age -6.789 3.146 -.338 -2.158 .038 
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Race was coded as white and non-white for comparison of nearly equal groups. Race was 
not significantly related to other prescription practices. No significant differences were found for 
gender and age related to prescription practices (Table 10). 
Table 10 
Correlations: Gender, Age, and Race Relationship to Psychotropic Prescription Practices 
Variables Total # Psychotropic Medications 
Psychotropic 
Polypharmacy 
Gender -.093 -.056 
Race -.170 .005 
Age -.063 -.016 
*p<.05, **p<.01, ***p<.001  
 
Hypotheses 6 and 7 
Patients with prior histories of self-harm, suicide attempts, institutional aggression, or 
lengthier occurrences of psychiatric hospitalization will be prescribed a greater number of 
psychotropic medications. Additionally, patients with prior histories of self-harm, suicide 
attempts, institutional aggression, or lengthier occurrences of psychiatric hospitalization will 
experience greater antipsychotic and mood-stabilizing polypharmacy.  Poisson and logistic 
regression analyses were used to assess the relationship between behavioral factors and 
psychotropic medication prescription practices for the total sample of 182 participants. 
Behavioral factors include history of self-harm, history of suicide attempts, and history of 
institutional aggression. Total ACE score and an ACE score of four or more served as 
independent variables. Mediating variables included history of self-harm, history of suicide, 
history of aggression, and institutionalization history. Total number of psychotropic medications 
prescribed and psychotropic polypharmacy served as dependent variables.  
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History of self-harm. A significant Poisson regression model predicting psychotropic 
prescription practices emerged, with history of self-harm being predictive of higher numbers of 
psychotropic medications (Table 11). Persons with history of self-harm are expected to have 
1.832 (95% CI [0.714, 0.910], p=0.018) times greater the number of psychotropic medications 
prescribed. Logistic regression analysis produced a significant model of the effects of history of 
self-harm on presence of psychotropic polypharmacy (χ2 = 10.436, Nagelkerke’s R2 = 0.230, p = 
0.001). Specifically, a history of self-harm was associated with a 5.060 increased likelihood of 
psychotropic polypharmacy (95% CI [3.957, 6.889], p=0.003). 
Table 11 
History of Self-Harm Predictive of Increased Psychotropic Medication Practices 
 B SE Wald χ2 p Exp(B) 
# Psychotropic Medications .584 .278 5.605 .018 1.832 
Psychotropic Polypharmacy 1.621 .546 8.831 .003 5.060 
  
Logistic and Poisson regression analyses were used to investigate the effect of total ACE 
score, high ACE score, and history of self-harm on total psychotropic medications prescribed 
and psychotropic polypharmacy. Mediation analyses were conducted for those variables, as an 
initial significant relationship was found.  
Results indicated that total ACE score was significantly predictive of total number of 
prescribed psychotropic medications (path c=.244, SE=.087, p=.006). Total ACE score was a 
significant predictor of a history of self-harm behaviors (path a =.409, SE = .086, p < .001). 
However, history of self-harm did not significantly predict the total number of psychotropic 
medications prescribed (path b=.650, SE=.408, p=.061) and, therefore, did not support a 





Mediation Analyses of ACE Score and Total Number Psychotropic Medications by History of 
Self-Harm 
Regression paths B SE t Wald p 
Mediation a path (ACE Score on Hx 
Self-harm) .409 .086 - 22.433 <.001 
Mediation b path (Hx Self-harm on # 
Psy Medications) .650 .408 1.591 - .061 
Total Effect c path (ACE Score on # 
Psy Medications) .244 .087 2.809 - .006 
Direct Effect c’ (ACE Score on # Psy 
Medications with Hx Self-harm 
mediator) 
.186 .094 1.973 - .114 
No mediation (b path), therefore no indirect effect calculated.  
 
Results indicated that having four or more ACEs was significantly predictive of total 
number of prescribed psychotropic medications (path c=.818, SE=.439, p=.045). An ACE score 
of four or greater was also a significant predictor of history of self-harm (path a =1.239, 
SE=.368, p=.001). Within this model, history of self-harm significantly predicted total number of 
psychotropic medications (path b=.831, SE=.394, p=.037). Finally, having four or more ACEs 
was no longer a significant predictor of total number of psychotropic medications when 
controlling for history of self-harm (path c’=.567, SE=.453, p=.213), consistent with full 
mediation (Figure 3).  
 
 
Figure 3. Full Mediation of 4+ ACE Score and Total Number Psychotropic Medications by 
History of Self-Harm  
4+ ACE score 
History of self-harm 
Number psychotropic 
medications 
c =0.818, p=0.045 
c’=0.;567, p=0.213 
a =1.239, p=0.001 b =.831, p=0.037 
53 
Approximately 33% of the variance in psychotropic prescriptions was accounted for by 
having four or more ACEs and history of self-harm (R2=.326). The indirect effect was tested 
using a bootstrap estimation approach with 5000 samples (Adjei & Karim, 2016). These results 
indicated the indirect coefficient was significant (b=1.030, SE=.217, 95% CI [.432, 1.416]; Table 
13). 
Table 13 
Mediation Analyses of 4+ ACE Score and Total Number Psychotropic Medications by History of 
Self-Harm 
Regression paths B SE t Wald p 95% CI 
Mediation a path (4+ ACE 
Score on Hx Self-harm) 1.239 .368 - 11.342 .001  
Mediation b path (Hx Self-
harm on # Psy 
Medications) 
.831 .394 2.109 - .037  
Total Effect c path (4+ 
ACE Score on # Psy 
Medications) 
.818 .439 1.861 - .045  
Direct Effect c’ (4+ ACE 
Score on # Psy 
Medications with Hx Self-
harm mediator) 
.567 .453 1.252 - .213  
Indirect Effect (c – c’) 
bootstrapped [95% CI] 1.030 .217    [.432, 1.416] 
 
Results indicated that total ACE score was significantly predictive of the presence of 
psychotropic polypharmacy (path c =.273, SE=.130, p=.035). As stated previously, total ACE 
score was a significant predictor of a history of self-harm behaviors (path a =.409, SE=.086, 
p<.001). A history of self-harm was a significant predictor of psychotropic polypharmacy (path b 
=1.469, SE=.581, p=.011). Total ACE score was no longer a significant predictor of 
psychotropic polypharmacy after controlling for history of self-harm (path c’ = .097, SE=.137, 




Figure 4. Full Mediation of Total ACE Score and Psychotropic Polypharmacy Relationship by 
History of Self-Harm  
 
Approximately 52% of the variance in psychotropic polypharmacy was accounted for by 
total ACE score and history of self-harm (R2 = .521). The indirect effect was tested using a 
bootstrap estimation approach with 5000 samples (Adjei & Karim, 2016).. These results 
indicated the indirect coefficient was significant (b =.601, SE=.061, 95% CI [.265, .926]; Table 
14). Total ACE score was associated with a .60 increase in the likelihood of being prescribed 
four or more psychotropic medications, as mediated by history of self-harm. 
Table 14 
Mediation Analyses of Total ACE Score and Psychotropic Polypharmacy by History of Self-
Harm 
Regression paths B SE Wald p 95% CI 
Mediation a path (ACE Score on 
Hx Self-harm) .409 .086 22.433 <.001  
Mediation b path (Hx Self-harm 
on Psy Polypharmacy) 1.469 .581 6.403 .011  
Total Effect c path (ACE Score 
on Psy Polypharmacy) .273 .130 4.426 .035  
Direct Effect c’ (ACE Score on 
Psy Polypharmacy with Hx Self-
harm mediator) 
.776 .354 4.812 .028  
Indirect Effect (c – c’) 
bootstrapped [95% CI] .601 .061   [.265, .926] 
 
 An ACE score of four or higher was significantly predictive of psychotropic 
polypharmacy (path c =1.634, SE=.767, p=.033). Having four or more ACEs was a significant 
Total ACE score 
History of self-harm 
Psychotropic 
polypharmacy 
c = 0.273, p=0.035 
c’= 0.097, p=0.478 
a = 0.409, p<0.001 b =1.469, p=0.011 
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predictor of a history of self-harm (path a =1.239, SE=.368, p=.001). History of self-harm 
behaviors was a significant predictor of psychotropic polypharmacy (path b =1.427, SE=.557, 
p=.010). An ACE score of four or higher was no longer significantly predictive of psychotropic 
polypharmacy after controlling for history of self-harm (path c’=1.164, SE=.792, p=.142), 
consistent with full mediation (Figure 5).  
 
 
Figure 5. Full Mediation of 4+ ACE Score and Psychotropic Polypharmacy by History of Self-
Harm 
 
Approximately 19% of the variance in psychotropic polypharmacy was accounted for by 
an ACE score of four or greater and history of self-harm (R2=.193). These results indicated the 
indirect coefficient was significant (b =1.768, SE=.471, 95% CI [1.026, 1.954]; Table 15).  
Table 15 
Mediation Analyses of 4+ ACE Score and Psychotropic Polypharmacy by History of Self-Harm 
Regression paths B SE Wald p 95% CI 
Mediation a path (4+ ACE Score on 
Hx Self-harm) 1.239 .368 11.342 .001  
Mediation b path (Hx Self-harm on 
Psy Polypharmacy) 1.427 .557 6.571 .010  
Total Effect c path (4+ ACE Score on 
Psy Polypharmacy) 1.634 .767 4.535 .033  
Direct Effect c’ (4+ ACE Score on 
Psy Polypharmacy with Hx Self-harm 
mediator) 
1.164 .792 2.156 .142  
Indirect Effect (c – c’) bootstrapped 
[95% CI] 1.768 .471   [1.026, 1.954] 
4+ ACE score 
History of self-harm 
Psychotropic 
polypharmacy 
c =1.634, p=0.033 
c’=1.164, p=0.142 
a =1.239, p=0.001 b =1.427, p=0.010 
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History of suicide. No significant relationship was found when examining the 
association between history of previous suicide attempts, and psychotropic prescription practices 
was not significant (see Table 4). 
History of institutional aggression. A significant model relating history of aggression 
and psychotropic prescription practices emerged (Table 16). History of aggression was predictive 
of total number of psychotropic medications (0.570, 95% CI [0.397, 0.817], p = 0.002). Logistic 
regression results also indicated a significant relationship between history of aggression and 
presence of psychotropic polypharmacy (χ2 = 5.767, Nagelkerke’s R2 = 0.073, p = 0.016). 
Participants with a history of aggression were 5.444 (p=0.013) times more likely to experience 
psychotropic polypharmacy than those without a history of aggression.  
Table 16 
Aggression Relationship to Psychotropic Medication Practices 
 B SE Wald χ2 p Exp(B) 
# Psychotropic Medications .562 .184 9.343 .002 .570 
Psychotropic Polypharmacy 1.695 .682 6.166 .013 5.444 
 
More specifically, Poisson regression produced a model predictive of a higher number of 
mood stabilizing and antipsychotic medications for persons with a history of aggression. Persons 
with history of aggression are expected to have a mood stabilizer/antipsychotic medication rate 
1.488 (95% CI [1.286, 1.832], p = 0.008) times greater than those without history of aggression. 
Logistic regression analysis produced a significant model of the effects of history of aggression 
on mood stabilizer polypharmacy (χ2 = 6.226, Nagelkerke’s R2 = 0.082, p = 0.013). Specifically, 
participants with a history of aggression were 5.460 (p=0.013) times more likely to be subject to 
mood stabilizer polypharmacy than those without a history of aggression. 
 
57 
 Results indicated that total ACE score was significantly predictive of total number of 
prescribed psychotropic medications (path c=.244, SE=.087, p=.006). However, total ACE score 
did not significantly predict of a history of aggression (path a =.246, SE= .162, p=.129). 
Therefore, a meditational relationship of total ACE score and psychotropic medication practices 
by history of aggression was not statistically supported (Table 17).  
Table 17 
Mediation Analyses of Total ACE Score and Psychotropic Medication Practices by History of 
Institutional Aggression 
Regression paths B SE t Wald p 
Mediation a path (ACE Score on Hx 
Institutional Aggression)1 .246 .162 - 2.300 .129 
Mediation b path (Hx Institutional 
Aggression on # Psy Medications) 2.084 .683 3.052 - .003 
Total Effect c path (ACE Score on # 
Psy Medications) .212 .086 2.463 - .015 
Direct Effect c’ (ACE Score on # Psy 
Medications with Hx Institutional 
Aggression mediator) 
.244 .087 2.809 - .006 
Mediation a path (ACE Score on Hx 
Institutional Aggression) .246 .162 - 2.300 .129 
Mediation b path (Hx Institutional 
Aggression on Psy Polypharmacy) 1.505 .694 - 4.705 .030 
Total Effect c path (ACE Score on Psy 
Polypharmacy) .273 .130 - 4.426 .035 
Direct Effect c’ (ACE Score on Psy 
Polypharmacy with Hx Institutional 
Aggression mediator) 
.238 .133 - 2.197 .074 
No mediation (a path), therefore no indirect effect calculated. 
 
Similarly, an ACE score of four or higher was significantly predictive of total number of 
psychotropic medications (path c=.818, SE=.268, p=.045). Having four or more ACEs was not 
significantly predictive of a history of aggression (path a =.840, SE= .784, p=.284); therefore, a 
mediation relationship between ACE score of four or greater and psychotropic medications with 
history of aggression was not supported (Table 18).  
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Table 18 
Mediation Analyses of 4+ ACE Score and Psychotropic Medication Practices by History of 
Institutional Aggression 
Regression paths B SE t Wald p 
Mediation a path (4+ ACE Score 
on Hx Institutional Aggression) .840 .784 - 1.147 .284 
Mediation b path (Hx Institutional 













Total Effect c path (4+ ACE 
Score on # Psy Medications) .818 .439 1.861 - .065 
Direct Effect c’ (4+ ACE Score 
on # Psy Medications with Hx 
Institutional Aggression mediator) 
.702 .434 1.618 - .108 
Mediation a path (4+ ACE Score 
on Hx Institutional Aggression) .840 .784 - 1.147 .284 
Mediation b path (Hx Institutional 
Aggression on Psy 
Polypharmacy) 
1.520 .697 - 4.752 .029 
Total Effect c path (4+ ACE 
Score on Psy Polypharmacy) 1.634 .767 - 4.535 .033 
Direct Effect c’ (4+ ACE Score 
on Psy Polypharmacy with Hx 
Institutional Aggression mediator) 
1.528 .777 - 3.870 .049 
No mediation (a path), therefore no indirect effect calculated.  
 
History of psychiatric hospitalizations. A lengthier history of psychiatric 
hospitalizations, as measured by number of previous admissions, was predictive of several varied 
psychotropic medication prescription practices. A significant Poisson regression model 
predicting psychotropic prescription practices emerged (Table 19), with lengthier history of 
psychiatric hospitalizations being predictive of higher numbers of psychotropic medications. For 
every additional hospitalization, a 1.007 (95% CI [1.000, 1.014], p = 0.038) increase in the 
number psychotropic medications, and, more specifically, a 1.012 (95% CI [1.002, 1.022], p = 




Lengthier History of Psychiatric Hospitalization Predicive of Psychotropic Prescription 
Practices 
 B SE Wald χ2 p Exp(B) 
# Psychotropic Medications .007 .004 4.289 .038 1.007 
Psychotropic Polypharmacy .268 .074 5.349 .017 1.012 
 
Total ACE score was significantly predictive of total number of psychotropic 
medications (path c=.244, SE=.087, p=.006) and psychotropic polypharmacy (path c =.273, 
SE=.130, p=.035). No significantly predictive relationship was found for total ACE score and 
lengthier institutionalization history; therefore, no meditational relationship was supported 
(Table 20).  
Table 20 
Mediation Analyses of Total ACE Score and Psychotropic Medication Practices by Number of 
Psychiatric Admissions 
Regression paths B SE t Wald p 
Mediation a path (ACE Score on # 
Psychiatric Hospitalization) .870 .493 2.026 - .045 
Mediation b path (# Psychiatric 
Hospitalization on # Psy 
Medications) 
.032 .019 1.709 - .090 
Total Effect c path (ACE Score on # 
Psy Medications) .244 .087 2.809 - .006 
Direct Effect c’ (ACE Score on # Psy 
Medications with # Psychiatric 
Hospitalization mediator) 
.220 .090 2.437 - .016 
Mediation a path (ACE Score on # 
Psychiatric Hospitalization) .576 .431 1.335 - .184 
Mediation b path (# Psychiatric 
Hospitalization on Psy 
Polypharmacy) 
.030 .027 - 1.246 .264 
Total Effect c path (ACE Score on 
Psy Polypharmacy) .273 .130 - 4.426 .035 
Direct Effect c’ (ACE Score on Psy 
Polypharmacy with # Psychiatric 
Hospitalization mediator) 
.248 .132 - 3.534 .060 
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Having four or more ACEs was significantly associated with total number of 
psychotropic medications (path c =818, SE=.439, p=.033) and psychotropic polypharmacy (path 
c =1.634, SE=.767, p=.065); however, no significant relationship was found between an ACE 
score of four or higher and lengthier history of institutionalization (path a =3.229, SE=2.145, 
p=.134; Table 21). 
Table 21 
Mediation Analyses of 4+ ACE Score and Psychotropic Medication Practices by Number of 
Psychiatric Admissions 
Regression paths B SE t Wald p 
Mediation a path (4+ ACE Score 
on # Psychiatric Hospitalization) 5.147 2.138 2.408 - .018 
Mediation b path (# Psychiatric 
Hospitalization on # Psy 
Medications) 
.035 .019 1.802 - .074 
Total Effect c path (4+ ACE 
Score on # Psy Medications) .818 .439 1.861 - .065 
Direct Effect c’ (4+ ACE Score 
on # Psy Medications with # 
Psychiatric Hospitalization 
mediator) 
.650 .463 1.405 - .163 
Mediation a path (4+ ACE Score 
on # Psychiatric Hospitalization) 3.229 2.145 1.506 - .134 
Mediation b path (# Psychiatric 
Hospitalization on Psy 
Polypharmacy) 
.026 .026 - .979 .322 
Total Effect c path (4+ ACE 
Score on Psy Polypharmacy) 1.634 .767 - 4.535 .033 
Direct Effect c’ (4+ ACE Score 
on Psy Polypharmacy with # 
Psychiatric Hospitalization 
mediator) 
1.498 .782 - 3.671 .055 
 
Hypothesis 8 
Higher rates of polypharmacy will yield a greater number of medications prescribed to 
address pharmacological side effects. A linear regression was calculated to predict the number of 
medications prescribed to aid with pharmacological side effects based on total number of 
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medications prescribed (Table 22). A significant equation was found (F(1, 129)=8.457, 
p=0.004), with an R2 of  0.248.  
Table 22 
Number of Medications Prescribed Effect on Medications Prescribed to Address 
Pharmacological Side Effects 
 B SE β t p 
# Side Effect Medications .048 .016 .248 2.908 .004 
      
 
Additionally, linear regression analysis (Table 23) indicated that the total number of different 
psychotropic medications was predictive of number of medications prescribed to aid with 
pharmacological side effects, with 32.9% of the variance explained (F(1, 129)=15.651, p<0.001).  
Table 23 
Number of Different Types of Psychotropic Medications Prescribed Effect on Medications 
Prescribed to Address Pharmacological Side Effects 
 B SE β t p 
# Side Effect Medications .126 .032 .329 3.956 <.001 
 
Unexpectedly, a significant inverse relationship was found showing the more mood 
stabilizers, anxiolytics, and or antipsychotics prescribed, the fewer number of medications were 
prescribed to address pharmacological side effects (F(1, 129)=4.444, p=.037), with an R2 of 
0.033. Participants’ side effect medications decreased 0.243 for each mood stabilizer, anxiolytic, 





Little research has examined the relationship between ACEs, related negative outcomes, 
and psychotropic prescription practices. No research to date has examined these relationships 
within forensic mental health populations, who experience markedly increased ACEs, 
psychopathology, and polypharmacy. This study evaluated the presence of ACEs and their 
impact on prescription practices, as well as the relationship between ACEs, prescription 
practices, and specific behavioral markers of mental and emotional health.  
 Participants in the current sample evidenced rates of ACEs that exceed those reported in 
community samples, with one-fourth having experienced four or more childhood adversities. The 
more childhood adversity and dysfunction experienced, the poorer the mental health outcomes, 
with total ACE score predicting an increased number of mental health diagnostic categories. 
Participants were diagnosed, on average, with three to four distinct mental health diagnostic 
symptom categories. Furthermore, nearly half of the participants were diagnosed with a mood 
disorder and three-fifths with a psychotic disorder.  
 As expected, the more mental health disorder categories a participant was diagnosed 
with, the more psychotropic medications were prescribed and the greater the risk of psychotropic 
polypharmacy. Participants were prescribed approximately five psychotropic medications in 
total, and, on average, approximately four different types of psychotropic medications. For those 
diagnosed with at least one serious mental illness (SMI), the risk of being prescribed two or more 
antipsychotic medications was nearly three-fold.  
 Regardless of number of mental health diagnoses, a graded relationship was established 
between ACE score and prescribed psychotropic medications. As number of ACEs increased, the 
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risk of psychotropic polypharmacy increased as well. For those who endorsed higher-end ACE 
scores, there was a five times greater risk of experiencing psychotropic polypharmacy compared 
to those with fewer than four ACEs. More specifically, those with four or more ACEs were over 
three times as likely to be prescribed antipsychotic medications regardless of an SMI diagnosis.   
Demographic Factors 
 Other factors and their relationship to prescription practices and ACE score were 
explored. In relation to demographic factors, white participants were prescribed psychotropic 
medications far earlier in life. In fact, on average, white participants received their first 
psychotropic prescription in adolescence as compared to non-white participants who were not, 
on average, prescribed a psychotropic medication until early adulthood. There are several 
potential explanations. Within minority populations, some studies have suggested higher 
prevalence of psychiatric disorders (Pumariega, Rogers, & Rothe, 2005); however, many 
minority youth who display disruptive or aggressive behaviors are referred to the juvenile justice 
system without consideration of the possibility that they may be experiencing untreated mental 
health problems (Bronsard et al., 2017; Garland, Hough, McCabe, Yeh, Wood, & Aaron, 2001).  
Furthermore, significant diagnostic disparities have been found within samples of minority 
youths. Some evidence suggests question phrasing may lead to response bias in minority 
populations (Alegria, Vallas, & Pumariega, 2010). These behavioral and diagnostic assumptions 
may lead to lower estimations of mental health needs, thus delaying pharmacologic intervention.  
Should a person require psychotropic medications related to specific diagnosed mental 
health conditions, the discrepancy in prescription practices by race may additionally be explained 
by the general disparities in access to healthcare and treatment for mental illness. These 
disparities have persisted, with fewer racial minorities having health insurance and fewer 
64 
receiving mental health treatment (U.S. Department of Health & Human Services, 2015). 
Additionally, racial minorities hold more conservative beliefs concerning mental illness and 
receiving related services. Ward and colleagues (2013) found that black or African American 
individuals perceived greater stigma related to psychological diagnoses and help-seeking 
behaviors, which led to participants more limitedly acknowledging psychological problems and 
being minimally open to seeking mental health services. The health care disparities and cultural 
stigma may further explain why white participants received their first psychotropic medication at 
a much younger age than non-white participants. 
Length and Prior History of Hospitalization 
Higher incidents of prior hospitalization increased the likelihood of higher rates of 
psychotropic medications. More specifically, for each additional hospitalization, the likelihood 
of being prescribed two or more mood stabilizers increased. Unexpectedly, patients with longer 
hospitalizations did not showcase different trends in psychotropic prescription practices in 
comparison with those with shorter current hospitalization. Previous studies have identified 
associations between specific types of polypharmacy practices (e.g., antipsychotic 
polypharmacy) and lengthier hospitalizations (e.g., Suokas et al., 2012); however, these findings 
may be more representative of factors that would yield lengthier hospitalizations, like severity of 
psychological symptoms and related behavioral consequences. Additionally, patients receiving 
more concerning antipsychotic polypharmacy regimens are often admitted with this regimen, or 
it is initiated within the first six months of hospitalization (Lacasse, 2014), suggesting length of 
hospitalization is not a causal factor of psychotropic polypharmacy. It may be more appropriate 
to consider length of hospitalization as a marker for more severe and chronic illness, rather than 
as a risk factor for psychotropic polypharmacy.  
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With each increasing number of independent psychiatric hospitalizations, there may be an 
opportunity at each admission intake for re-evaluation and review of recent mental health and 
behavioral history to determine current medication need. This re-evaluation may yield a change 
in perception of need by providers because of the renewed ability to consider previously 
unaccounted for history and determine the change or persistence in current symptom 
presentation. Lacasse (2014) concluded that being previously committed to a psychiatric facility 
may elicit a stronger perception of risk and dangerousness, thus, influencing prescription 
practices. 
While ACE score was not predictive of the number of prior hospitalizations when 
demographic factors and number of mental health diagnostic categories were taken into account, 
lengthier history of prior hospitalizations may represent persistence of mental illness and 
behavioral concerns. A more detailed examination of the reasons for various past hospitalizations 
may more effectively allow for an understanding of the relationship of ACE score and 
prescription practices in the context of previous hospitalizations.  
Behavioral Markers 
Several behavioral factors that may evidence more severe and chronic emotional and 
mental health concerns were explored. These behavioral markers must be considered within the 
context of the type of data collected (i.e., prescription count data). First line psychotropic 
medication treatment guidelines suggest giving an individual drug an adequate trial at therapeutic 
levels and within specific dosage recommendations to determine efficacy before considering 
polypharmacy (Moller et al., 2014). The data collected for this study did not allow for analysis of 
dosing. As such, behavioral histories of self-harm, suicide attempts, and institutional aggression 
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may have been addressed by adjusting the dosage of current prescriptions rather than adding 
additional psychotropic medications.  
History of Self-Harm 
A history of self-harm was associated with higher rates of psychotropic medications, with 
a risk of nearly five times greater for psychotropic polypharmacy regardless of types of mental 
health diagnoses.  Taken together, experiencing childhood adversity and familial dysfunction 
leads to an increased number of psychotropic medications and psychotropic polypharmacy for 
self-harm behaviors. Abuse and neglect in childhood can contribute to difficulty regulating 
emotional responses and result in the employment of maladaptive emotional regulation behaviors 
(e.g., self-harm; Cleare et al., 2018). These behaviors are most likely expressions of symptomatic 
fluctuation and often in the context of emotional dysregulation and impulsivity. As a result, 
psychotropic polypharmacy may be a common outcome in an attempt to provide symptomatic 
relief (Madan et al., 2015).  
History of Suicide Attempts 
Suicide attempt history did not reveal varied prescription practices. While persons with 
suicidal behaviors may evidence more severe psychopathology, there is limited evidence that 
psychotropic medication management reduces long-term suicide risk (Baldesarini & Tondo, 
2012). As a result, history of suicide attempts may have lesser impact on medication 
management than the acute nature of active suicidal ideation or behaviors.  
History of Institutional Aggression 
History of institutional aggression was predictive of higher numbers of psychotropic 
medications, as those with a history of aggression were 5.5 times more likely to experience 
psychotropic polypharmacy. Regardless of being diagnosed with a mood disorder or SMI, 
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participants with a history of institutional aggression were 1.5 times more likely to be prescribed 
multiple mood stabilizers and antipsychotics. These patients were five times more likely to be 
subject to mood stabilizer polypharmacy. This is consistent with and extends prior research in 
similar samples, in that patients in forensic inpatient settings are often prescribed at least one 
antipsychotic or mood stabilizer, often at higher dosing, to manage actual or perceived violent 
behavior (Deb et al., 2015; Krakowski, 2008; Lacassee, 2014; Swanson et al., 2008). 
Cumulative ACE score was not predictive of history of institutional aggression. This may 
be a result of a ceiling effect, as over 92% of individuals had history of institutional aggression. 
This saturation in the sample, without further detail, may have prevented distinguishing a more 
specific relationship between ACE score and institutional aggression. Previous research has 
identified a positive link between experiences of abuse, neglect and household dysfunction 
during childhood and likelihood of perpetrating later violence (e.g., Duke et al., 2010; Reavis et 
al., 2013; Whitfield et al., 2003). However, definitive causal models have not been established in 
available research. Additionally, much of the research examining aggression and ACEs focuses 
on aggressive acts outside of the institutional environment and, if more specific, by behavioral 
categories of aggression (Goedhard, Stoller, Nijman, Egberts, & Heerdink, 2007) or aggression 
type (Dudeck et al., 2016). Research indicates different predictors for community versus 
institutional aggression (e.g., Young, Misch, Collins, & Gudjonsson, 2011). Further examination 
of ACEs, aggression, and other related factors is required to fully understand these relationships. 
Psychotropic Polypharmacy Side Effect Management 
Psychotropic polypharmacy was not unexpected, particularly in the context of 
multimorbidity common in forensic inpatient populations (Gnijdic et al., 2017). With most 
participants being diagnosed with multiple mental health disorders, it could be argued that a 
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regimen of one medication for each disorder is strictly rational. Nevertheless, this approach can 
lead to an increased side effect burden and problematic pharmacological interactions. This is 
especially true considering medication regimens that include treatment of medical diagnoses. For 
the current study’s participants, the more medications prescribed, the higher the need for 
medications to address medication side effects. Particularly, higher rates of psychotropic 
medications had an equivocal need for increased prescriptions of medications to address related 
and often serious side effects.  
Unexpectedly, an increase in mood stabilizing, anxiolytic, and/or antipsychotic 
medications resulted in a slight reduction in prescriptions to address medication side effects. 
Research suggests an increased need for medications to address extrapyramidal side effects with 
increased dosage and number of antipsychotics taken, as well as lengthier time taking these 
medications (Armstrong & Temmingh, 2017; Carnahan et al., 2006). While anticholinergic 
agents are commonly used medications for extrapyramidal side effects (Pringsheim et al., 2011), 
there is an increased risk of compounded side effects if these are combined with atypical 
antipsychotics (Campbell et al., 2009; Lieberman, 2004). Less commonly, dopamine agonist 
agents are also used to treat extrapyramidal side effects (Pringsheim et al., 2011). Dopamine 
receptor agonists have efficacy as an adjunctive intervention for treatment-resistant depression 
and mood disorders (Hori & Kunugi, 2012; Romeo, Blecha, Locatelli, Benyamina, & Martelli, 
2018). Additionally, anxiolytics have been found to partially mimic dopamine agonists 
(Bartoszyk, 1998). Taken together, it may be that the addition of an anxiolytic helped manage 
extrapyramidal side effects, or that in the treatment of mood concerns a dopamine agonist or 
partial agonist was added to the medication regimen and, thus, aided in the management of 
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extrapyramidal side effects without the need to add a specific medication only to address these 
side effects.  
Future Directions 
 The current findings provide valuable insight into the relationships between ACEs, 
psychopathology symptomology, and psychotropic prescription practices for persons within a 
secure forensic inpatient setting. This sample of individuals represents a unique and understudied 
group within the context of ACEs research and psychotropic polypharmacy.   
ACE score indicates the presence of a limited set of adversities in childhood. It is not an 
all-encompassing indicator of childhood experience, however. In populations with high 
incidences of ACEs, there are other potential predictors that may emerge that more completely 
and precisely explain the impact of childhood adversity and household dysfunction on mental 
health outcomes, symptoms of mental illness, institutional aggression, and related prescription 
practices. Accordingly, future research should consider other components of adversity, including 
duration and severity of maltreatment, community adversity correlates (e.g., persistent violence 
within community), and specific ACE item relationship to identified outcomes. To more fully 
understand the role of early trauma and dysfunction, exploring the relationship of individual 
ACE items to demographic factors, mental health outcomes, and related prescription practices is 
a needed next step.  
 Also, examining prescription practices could be expanded beyond their on-label uses for 
diagnosed mental illnesses. The current study categorized prescriptions based on their on-label 
approved treatments. Future studies may more precisely distinguish rates and relationships to 
psychotropic polypharmacy by investigating the intended purpose of the medication (e.g., SSRI 
prescribed for sleep concerns rather than antidepressant). Additionally, having access to 
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medication dosing would provide a more complete picture of prescription practices. This is 
specifically concerning for those exhibiting self-harm, suicidality, and aggressive behaviors. 
While additional prescriptions may be the response to such behaviors, increasing the dosage of 
current medications may be the first line medication management response. This increase in 
dosage would not evidence increased polypharmacy practices, but may still carry with it negative 
side effects. As such, it is important to understand the complete picture of prescription practices 
for the most effective treatment approaches to be developed and understood.  
 To better understand the relationship of length of hospitalization and prescription 
practices, future research should account for drug regimens at admission, alterations made after 
initial assessment, and alterations throughout admission until discharge. Understanding the 
timeline of prescriptions, particularly at admission and discharge, could allow for a more detailed 
model encompassing risk of polypharmacy in relation to characteristics of hospitalization. 
Furthermore, ascertaining the reason for previous hospitalizations may evidence insight into the 
impact of chronic emotional and mental health outcomes on prescription practices. This may lead 
to a more in-depth evaluation of diagnosis and symptomology and related prescription practices 
(e.g., schizoaffective disorder versus schizophrenia; those with SMI that do and do not suffer 
with hallucinations). Taking into account the pervasiveness of certain symptomologies, historical 
versus current/acute symptoms, and the functional context of behaviors in the context of ACEs 
and prescription practices will allow for a more in depth perspective on these relationships, 
informing future prevention and intervention methods.  
Limitations 
There are a number of limitations of the current research. The sample was drawn from 
only one facility, which may limit generalizability. While the sample is smaller in size (N=182), 
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this is representative of the small nature of forensic mental health populations and is consistent 
with other empirical research focusing on this group.  Despite the small sample, my findings are 
still informative for those working with these understudied groups. Additionally, this study was 
comprised of retrospective, archival data, which may be subject to recording error and does not 
allow for varied exploration of specific data points. However, the inclusion and exclusion criteria 
allow for a selection of records with detailed reports corroborated by participants’ family 
members and official agencies.  
Prescription count data allowed for several key analyses, but a more detailed examination 
of relationships would have been possible with additional information (e.g., medication dosing, 
length of time taking specific medications). A strength of the current study is that the data used 
are prescription data within a setting that has controlled medication distribution. This type of 
data reflects provider prescription practices and a stricter monitoring of prescribed medication 
adherence. As such, these data may be a more accurate portrayal of medications and adherence 
than self-report data.  
 The manner of recording data may also limit findings of the current study. Dichotomous 
recording of behavioral histories, though able to more conservatively estimate such a factor, 
provided limited information related to characteristics of aggression like pervasiveness, historical 
versus current, frequency, and severity. Future studies should seek to examine relationships 
between ACEs, behavioral histories, and prescription practices in less restricted ways. 
Conclusion 
Nuanced findings addressing the study aims allowed for filling gaps and extending 
current literature. The patterns and impact of polypharmacy were established and the relationship 
between prescription practices, ACEs, and related behavioral markers were examined. 
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The stark intricacy and sheer rates of psychotropic prescriptions and polypharmacy are 
concerning for the treatment and eventual outcomes of these patients, as prior research suggests 
increased likelihood of adverse drug events, concerning side effects, and decreased life 
expectancy associated with polypharmacy and psychotropic polypharmacy practices. Diagnostic 
accuracy and clarification may aid in assessing treatment needs. Even with complex needs, 
prescribers must review pharmaceutical regimens regularly, and when contemplating the 
addition of a psychotropic medication, must verify that superfluous medications are discontinued 
and interactions can be accounted for on an individual basis.  
ACEs are a relevant consideration in the treatment of mental illness. Childhood adversity 
may lead to a lifetime of difficulty with managing emotional distress and symptoms of 
psychopathology. Pharmacological treatment may be necessary, particularly with populations 
who experience more complex mental health outcomes. However, a primary focus on 
psychotropic intervention can result in high rates of medications and polypharmacy with 
significant side effects. Individuals who have experienced higher incidents of childhood 
adversity may require unique treatment approaches, given additional associations between ACEs, 
aggression, self-harm, suicidality, and other factors associated with increased perceived 
behavioral and mental health symptoms that may prompt polypharmacy considerations.  
Additional treatment responses and incorporation of non-pharmacological intervention to 
circumvent the potential for psychotropic polypharmacy and related negative consequences is a 
crucial goal for these patients. Treatments that focus on addressing learned maladaptive coping 
strategies as well as addressing the current problem behaviors with an eye to addressing 
functional need are warranted. This may allow for lessened dependence on psychotropic 
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medications as a means of managing the complex nature of emotional and mental health needs 
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